/
/
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Chapitres
- 00:04Titre
- 00:39Recipient Mouse Preparation and Bone Marrow Nucleated Cell (BMNC) Harvest
- 02:25BMNC Fluorescence-activated Cell Sorting (FACS) and Hematopoietic Stem Cell Transplantation (HSCT)
- 04:52Results: Representative HSCT Analyses
- 06:08Conclusion
We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.
